Member Info for ConsDoms

Stu hasn't confirmed anything mrI. And even if he has inferred funding why on earth would you take that as a given?

It is a difficult watch. I’ve been glass half full for many years but to not have started trials and or secured funding by now is confounding. Its only my opinion but I think the wording in the RNSs around timeframes (or inferences) are misleading

Losta

18 September 2023: 'Prevail InfoWorks, Inc. to act as Contract Research Organization (CRO) for upcoming Phase I clinical study, expected to commence in 2023'.

9th September 2024: 'We are excited to begin our Phase I trials imminently at MD Anderson Cancer Center, a leading institution in cancer care, and look forward to expanding our efforts to the University of Pennsylvania Medical Center."

So I dont think it is unreasonable for those who have been here years and invested their hard earned to wonder why trials seem to have slipped

2/10 'This will follow the initiation of the adult clinical trial in HEMO-CAR-T at the MD Anderson Cancer Center, Texas, which is expected to commence later this year'

27/9 'Phase I clinical trials expected to begin shortly at M.D. Anderson Cancer Center ("MD Anderson") in Texas.

9/9 'We are excited to begin our Phase I trials imminently at MD Anderson Cancer Center, a leading institution in cancer care'

How do you know funding is about to be announced MrI?

Thanks RP20.

bring back Tuan!❤️

Wtf are you talking about WKW? there was some excitement at the MD Anderson news recently (cant see an issue with that).

go on then, point your finger i.e. name who ramped this to 6p and then walked away

Thanks Stu and JH. good debate!

Hi Stu,

I was curious as to your response to HKs observation below? (hope you dont mind HK Ive posted it again for Stu)

Stu

You chose a wrong example with Caribou Biosciences CB-012 CAR-T again (intentionally?).

CB-012 CAR-T is an allogeneic product modified using CRISPR-CAS9. Jennifer Doudna and Emmanuelle Charpentier were awarded a Nobel for CRISPER-CAS9 indeed. Doudna is advising Caribou. However, the “problem” of Caribou is not CRISPR, but rather the fact that it is using allogeneic T cells that target CLL-1. Allogeneic CAR T cells have problems in the clinic. HEMO is using autologous CAR-T and targets FLT3.

Echo that!

Dare we dream that such a confident statement ‘we are excited to begin our Phase 1 trials imminently’, means significant funding is almost in place (non dilutive)…

No post referenced clinical start dates as you state. allegations of inside information being relayed are completely unfounded.

No Stu. it is not clear. Micky allegation of inside information being divulged is incorrect. Unproven. No post removed.

Good night Stu

Your mistaken Stu, Im not frustrated. just making a correction like you like to. No posts have been removed.

Those that oversee here must have seen how pathetic any report was (if indeed there was one).

No posts have been removed Stu

Stu. complete nonsense and you know it. There was nothing in Indias post we didnt know already. Folk just making it to be something way bigger than it was (for their own agenda)

Really Stu. If someone reported the post from India as potential insider info god help them

We praise our lucky stars your criteria were met